Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome inhibitor. Sixty patients with relapsed and/or...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Kumar, Shaji K., Bensinger, William I., Zimmerman, Todd M., Reeder, Craig B., Berenson, James R., Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj, Di Bacco, Alessandra, Yu, Jiang, Shou, Yaping, Niesvizky, Ruben
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2014
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468583/
https://ncbi.nlm.nih.gov/pubmed/24904120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-548941
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg